Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization?

Circulation

Volumn 123, Issue 7, 2011, Pages 779-797

  Onuma, Yosinobu ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

biodegradable polymers; bioresorbable scaffold; coronary artery disease; coronary stent

Indexed keywords

ABSORBABLE SUTURE; ADIPIC ACID; ALLOY; ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; ANTINEOPLASTIC AGENT; BIOMATERIAL; EVEROLIMUS; MACROGOL; MAGNESIUM ALLOY; MOLECULAR SCAFFOLD; NITINOL; PACLITAXEL; POLY(ANHYDRIDE ESTER) SALICYLIC ACID; POLY(DESAMINOTYROSYLTYROSINE ETHYL ESTER)CARBONATE; POLY(ORTHO ESTER); POLYBUTYLENE TEREPHTHALATE; POLYCAPROLACTONE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; RAPAMYCIN; SALICYLIC ACID; UNCLASSIFIED DRUG;

ABSORPTION; ARTERY INTIMA PROLIFERATION; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADATION; BLEEDING; BLOOD VESSEL INJURY; CONTROLLED DRUG RELEASE; CORONARY ARTERY DILATATION; CORONARY STENT; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG STRUCTURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYDRATION; HYDROLYSIS KINETICS; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MOLECULAR WEIGHT; NONHUMAN; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTITUTION REACTION; SURGICAL EQUIPMENT;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CARDIOLOGY; CORONARY ARTERY DISEASE; HUMANS; POLYMERS; STENTS; TISSUE SCAFFOLDS;

EID: 79952057270     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.971606     Document Type: Review

References (104)

1. de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J. 1994;127:643-651. (Pubitemid 24124696)
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701-706. (Pubitemid 17036474)
3. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61-68. (Pubitemid 9229695)
4. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12:616-623.
5. Gruentzig AR, King SB III, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty: the early Zurich experience. N Engl J Med. 1987;316:1127-1132. (Pubitemid 17052502)
6. Kaltenbach M, Kober G, Scherer D, Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J. 1985;6:276-281. (Pubitemid 15063008)
7. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JH, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a timerelated phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361-371.
8. Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, King SB Jr, Gruentzig AR. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation. 1986;73:710-717. (Pubitemid 16081430)
9. Kimura T, Kaburagi S, Tamura T, Yokoi H, Nakagawa Y, Hamasaki N, Nosaka H, Nobuyoshi M, Mintz GS, Popma JJ, Leon MB. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation. 1997;96:475-483. (Pubitemid 27329423)
10. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation. 1996;94: 1247-1254. (Pubitemid 26307249)
11. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43. (Pubitemid 126426397)
12. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V, de Jaegere P, de Feyter PJ, Roelandt JR, Serruys PW. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol. 1995;75:772-777.
13. Luo H, Nishioka T, Eigler NL, Forrester JS, Fishbein MC, Berglund H, Siegel RJ. Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Arterioscler Thromb Vasc Biol. 1996;16:1393-1398. (Pubitemid 26378231)
14. Rodriguez AE, Santaera O, Larribau M, Fernandez M, Sarmiento R, Perez B, Newell JB, Roubin GS, Palacios IF. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Circulation. 1995;91:1397-1402.
15. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
16. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol. 1991;17:433-439.
17. Garratt KN, Edwards WD, Kaufmann UP, Vlietstra RE, Holmes DR Jr. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts: analysis of tissue obtained from 73 patients by directional atherectomy. J Am Coll Cardiol. 1991;17:442-448.
18. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med. 1994;331:489-495. (Pubitemid 24256751)
19. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501. (Pubitemid 24256752)
20. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation. 2007; 115:1433-1439.
21. Waksman R. Late thrombosis after radiation: sitting on a time bomb. Circulation. 1999;100:780-782. (Pubitemid 29398871)
22. Costa MA, Sabate M, van der Giessen WJ, Kay IP, Cervinka P, Ligthart JM, Serrano P, Coen VL, Levendag PC, Serruys PW. Late coronary occlusion after intracoronary brachytherapy. Circulation. 1999;100:789-792. (Pubitemid 29398874)
23. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195. (Pubitemid 32095401)
24. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. 2001;22:2125-2130. (Pubitemid 33091454)
25. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011. (Pubitemid 33027038)
26. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780. (Pubitemid 34586912)
27. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (last) events with drugeluting stents. J Am Coll Cardiol. 2005;45:2088-2092. (Pubitemid 40814135)
28. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521. (Pubitemid 39410418)
29. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440-1455. (Pubitemid 46648381)
30. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019. (Pubitemid 46376801)
31. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591. (Pubitemid 44881238)
32. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-678. (Pubitemid 46281313)
33. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-1140.
34. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Rademaker T, Wittebols K, Stoll HP. 5-Year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2009;55:1093-1101.
35. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-2441. (Pubitemid 46717966)
36. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-1510. (Pubitemid 46986103)
37. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
38. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166-170. (Pubitemid 43069032)
39. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46:231-236. (Pubitemid 40966848)
40. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910.
41. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, Lincoff AM, Stone GW. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936-1945. (Pubitemid 47579535)
42. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-1409.
43. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972.
44. Spuentrup E, Ruebben A, Mahnken A, Stuber M, Kolker C, Nguyen TH, Gunther RW, Buecker A. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation. 2005; 111:1019-1026. (Pubitemid 40354520)
45. Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009;2:255-260.
46. Shalaby SW, Burg KJL. Absorbable and Biodegradable Polymers (Advances in Polymeric Biomaterials). Boca Raton, FL: CRC Press; 2003.
47. Vert M. Bioabsorbable polymers in medicine: an overview. EuroIntervention. 2009;5:F9-F14.
48. Plastics guide for vocabulary in the field of degradable and biodegradable polymers and plastic items. 2006. CEN/Tech. Rep. 15351.
49. van der Giessen WJ, Slager CJ, van Beusekom HM, van Ingen Schenau DS, Huijts RA, Schuurbiers JC, de Klein WJ, Serruys PW, Verdouw PD. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. J Interv Cardiol. 1992;5:175-185.
50. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697. (Pubitemid 26320276)
51. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 1997;29:808-816. (Pubitemid 27128255)
52. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998;32:780-786. (Pubitemid 28435269)
53. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009;5:F15-F22.
54. Pitt CG, Gratzl MM, Kimmel GL, Surles J, Schindler A. Aliphatic polyesters II: the degradation of poly (dl-lactide), poly (epsiloncaprolactone), and their copolymers in vivo. Biomaterials. 1981;2:215-220. (Pubitemid 12195194)
55. Pitt CG, Zhong-wei G. Modification of the rates of chain cleavage of poly(-caprolactone) and related polyesters in the solid state. J Control Release. 1987;4:283-292. (Pubitemid 17034750)
56. Pitt CG, Chasalow FI, Hibionada YM, Klimas DM, Schindler A. Aliphatic polyesters, I: the degradation of poly(-caprolactone) in vivo. J Appl Polym Sci. 1981;26:3779-3787.
57. Weir NA, Buchanan FJ, Orr JF, Farrar DF, Dickson GR. Degradation of poly-l-lactide, part 2: increased temperature accelerated degradation. Proc Inst Mech Eng H. 2004;218:321-330.
58. Weir NA, Buchanan FJ, Orr JF, Dickson GR. Degradation of poly-llactide, part 1: in vitro and in vivo physiological temperature degradation. Proc Inst Mech Eng H. 2004;218:307-319.
59. Prabhu S, Hossainy S. Modeling of degradation and drug release from a biodegradable stent coating. J Biomed Mater Res A. 2007;80:732-741. (Pubitemid 46239086)
60. English JP, Perrin DE. Polyglycolide and polylactide. In: Wiseman DM, Kost J, Domb AJ, eds. Handbook of Biodegradable Polymers. Boca Raton, FL: CRC Press; 1998.
61. Kronenthal R. Biodegradable polymers in medicine and surgery. In: Kronenthal R, Oser Z, Martin E, eds. Polymers in Medicine and Surgery. New York, NY: Plenum Press; 1975:119-137.
62. Hollinger JO, Battistone GC. Biodegradable bone repair materials: synthetic polymers and ceramics. Clin Orthop Relat Res. 1986;290-305.
63. Onuma Y, Serruys P, Perkins L, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography (OCT) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human OCT images in the ABSORB trial. Circulation. 2010;122:2288-2300.
64. Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol. 2009;57:537-565.
65. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399-404. (Pubitemid 30490677)
66. Tsuji T, Tamai H, Igaki K, Hsu Y-S, Kosuga K, Hata T, Okada M, Nakamura T, Fujita S. Four-year follow-up of the biodegradable stent (Igaki-Tamai stent). Circ J. 2004;68:135.
67. Nishio S. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents. Eurointervenion. 2010;6:H44.
68. Post MJ, de Graaf-Bos AN, van Zanten HG, de Groot PG, Sixma JJ, Borst C. Thrombogenicity of the human arterial wall after interventional thermal injury. J Vasc Res. 1996;33:156-163. (Pubitemid 26089633)
69. Biamino G, Schmidt A, Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS Study. J Endovasc Ther. 2005;12:5.
70. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007;369:1869-1875. (Pubitemid 46829357)
71. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89:651-656.
72. Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Hartwig S, Harder C, Rohde R, Heublein B, Andreae A, Waldmann KH, Haverich A. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006;68:607-617. (Pubitemid 44546055)
73. Peeters P, Bosiers M, Verbist J, Deloose K, Heublein B. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. J Endovasc Ther. 2005;12:1-5. (Pubitemid 40229382)
74. Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR, Erne P, Haude M, Horrigan M, Ilsley C, Bose D, Bonnier H, Koolen J, Luscher TF, Weissman NJ. Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. J Am Coll Cardiol Cardiovasc Interv. 2009;2:312-320.
75. Eggebrecht H, Rodermann J, Hunold P, Schmermund A, Bose D, Haude M, Erbel R. Images in cardiovascular medicine: novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation. 2005;112:e303-e304.
76. Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, Ilsley C, Di Mario C, Erbel R, Waksman R, Dalby M. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention. 2009;4:481-484.
77. Bosiers M, Peeters P, D'Archambeau O, Hendriks J, Pilger E, Duber C, Zeller T, Gussmann A, Lohle PN, Minar E, Scheinert D, Hausegger K, Schulte KL, Verbist J, Deloose K, Lammer J. AMS insight: absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32:424-435.
78. Schulze R. REVA Medical, Inc. Bioresorbable stent. Presented at: Cardiovascular Revascularization Therapies Conference; March 7-9, 2007; Washington, DC.
79. Schultz R. REVA medical, inc. Bioresorbable technology. Presented at: Cardiovascular Revascularization Therapies Conference; April 3-6, 2006; Washington, DC.
80. Grube E. Bioabsorbable stent: the Boston Scientific and REVA technology. Presented at: EuroPCR; May 19-22, 2009; Barcelona, Spain.
81. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv. 2008;72:186-194.
82. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention. 2009;5:F58-F64.
83. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899-907. (Pubitemid 351384734)
84. Bruining N, Tanimoto S, Otsuka M, Weustink A, Ligthart J, de Winter S, van Mieghem C, Nieman K, de Feyter PJ, van Domburg RT, Serruys PW. Quantitative multi-modality imaging analysis of a bioabsorbable poly-l-lactic acid stent design in the acute phase: a comparison between 2-and 3D-QCA, QCU and QMSCT-CA. EuroIntervention. 2008;4:285-291.
85. Schaar JA, De Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E, Serruys PW, Van Der Steen AF. Characterizing vulnerable plaque features with intravascular elastography. Circulation. 2003;108:2636-2641. (Pubitemid 37466804)
86. Schaar JA, Regar E, Mastik F, McFadden EP, Saia F, Disco C, de Korte CL, de Feyter PJ, van der Steen AF, Serruys PW. Incidence of highstrain patterns in human coronary arteries: assessment with threedimensional intravascular palpography and correlation with clinical presentation. Circulation. 2004;109:2716-2719. (Pubitemid 38737916)
87. Bruining N, Verheye S, Knaapen M, Somers P, Roelandt JR, Regar E, Heller I, de Winter S, Ligthart J, Van Langenhove G, de Feijter PJ, Serruys PW, Hamers R. Three-dimensional and quantitative analysis of atherosclerotic plaque composition by automated differential echogenicity. Catheter Cardiovasc Interv. 2007;70:968-978.
88. Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis: a substudy of the ABSORB clinical trial. EuroIntervention. 2008;4:443-448.
89. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49:706-715. (Pubitemid 46205042)
90. Onuma Y, Serruys P, Ormiston J, Regar E, Webster M, Thuesen L, Dudek D, Veldhof S, Rapoza R. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010;6:447-453.
91. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
92. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimuseluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70:515-523. (Pubitemid 47597022)
93. Tanimoto S, Bruining N, van Domburg RT, Rotger D, Radeva P, Ligthart JM, Serruys PW. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol. 2008;52:1616-1620.
94. Okamura T, Garg S, Gutiérrez-Chico J, Shin E, Onuma Y, García-García H, Rapoza R, Sudhir K, Regar E, Serruys P. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimuseluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention. 2010;932-938.
95. Serruys PW, Onuma Y, Ormiston JA, Bruyne Bd, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: 6-month clinical and imaging outcomes. Circulation. 2010;122:2301-2312.
96. Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D. The firstgeneration drug-eluting stents and coronary endothelial dysfunction. J Am Coll Cardiol Cardiovasc Interv. 2009;2:1169-1177.
97. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658. (Pubitemid 34851922)
98. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954. (Pubitemid 30131694)
99. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol. 1999;33:1442-1452.
100. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J. 2000;64:1-12. (Pubitemid 30073654)
101. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-1664. (Pubitemid 23157347)
102. Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.
103. Serruys PW, Zijlstra F, Laarman GJ, Reiber HH, Beatt K, Roelandt J. A comparison of two methods to measure coronary flow reserve in the setting of coronary angioplasty: intracoronary blood flow velocity measurements with a Doppler catheter, and digital subtraction cineangiography. Eur Heart J. 1989;10:725-736. (Pubitemid 19233414)
104. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)